Product hub

Product hub: Targeted protein degradation – next-generation therapeutics

Posted: 27 September 2022 | | No comments yet

Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.

TPD approaches can completely remove pathogenic proteins, rather than just inhibiting their function, providing potential for more potent or broader pharmacology, improved selectivity and better sustained in vivo effects. There has been an increasing focus on assays such as three-dimensional (3D) cell culture, complex co-cultures and patient-derived cells, which can more accurately predict how a molecule will behave in vivo. We have also seen a recent increase in the use of bioinformatics and artificial intelligence (AI) techniques to identify new targets and re-purpose current molecules.

READ IN FULL